A novel gene therapy has achieved what scientists described as "impossible," completely eliminating aggressive brain tumors and preventing their recurrence in pre-clinical studies, offering new hope for treating glioblastoma.
Research published in the journal Nature details a breakthrough using Synthetic Super-Enhancers (SSEs), a technology designed by the company Trogenix. In a brain cancer model closely mimicking human glioblastoma, a single dose of the therapy led to the total disappearance of tumors in 83% of treated cases. Tumors began shrinking within one to two weeks and were fully eradicated over the following two to three weeks. Critically, the treatment provided durable protection, with no tumor recurrence observed over an 11-month follow-up period and no harmful side effects detected.
The therapy works as a sophisticated "Trojan horse." A harmless, engineered virus delivers genetic instructions specifically into glioblastoma cells. Once inside, these instructions compel the cancer cell to produce a toxic substance and simultaneously trigger a precise immune system attack against the tumor. Researchers reported that this activity remained undetected in healthy brain cells, indicating a high degree of selectivity for the aggressive cancer. "We can finally hit the tumour hard and early by using controlled gene therapy that has been designed to be highly selective for the most aggressive cancer cells," said Professor Steve Pollard, study lead and Chief Scientific Officer of Trogenix.
The findings represent a significant potential advance for a disease where treatment options have remained largely unchanged for over two decades. Glioblastoma is the most common and aggressive primary brain cancer in adults, with a notoriously poor prognosis and high rate of recurrence following standard surgery, radiation, and chemotherapy.
Trogenix plans to advance the therapy to human trials this year with a Phase I/II study named the ADePT trial. The research team and advocacy groups express cautious optimism, noting that while the pre-clinical results are exceptionally promising, the focus is now on a safe and efficient translation to clinical practice. The work underscores a growing pipeline of innovative approaches aiming to transform outcomes for patients with solid tumors, beginning with one of the most challenging cancers to treat.